<DOC>
	<DOCNO>NCT01499368</DOCNO>
	<brief_summary>To evaluate heal rate safety Lafutidine erosive esophagitis</brief_summary>
	<brief_title>A Multi-center , Randomized , Double-blind Phase III Clinical Trial Assess Compare Efficacy Safety Lafutidine , Famotidine Omeprazole-referenced Korean Erosive Esophagitis Patients</brief_title>
	<detailed_description />
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Lafutidine</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Famotidine</mesh_term>
	<criteria>Patients symptom heartburn diagnosis grade A D reflux esophagitis accord Los Angeles classification Gastric duodenal ulcer ( exclude ulcer scar ) Concurrent presence Barrett 's esophagus A history poor response H2RA PPI give recommend dose 8 week Other condition consider attend physician potentially affect assessment efficacy safety</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>